Last reviewed · How we verify
A Single-arm, Open, Multicenter, Phase II Study to Investigate the Efficacy and Safety of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.
Details
| Lead sponsor | Shanghai YingLi Pharmaceutical Co. Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 90 |
| Start date | 2021-04 |
| Completion | 2023-06 |
Conditions
- PTCL
Interventions
- YY-20394 treatment
Primary outcomes
- ORR — up to 12 months
Objective Response Rate